Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05060614

Analyses of Cerebrospinalfluid in Patients With Delirium

The current project aims to measure biomarkers in the cerebrospinalfluid (CSF) and serum samples from patients with delirium. We hope to uncover new insights into the pathophysiology of delirium and explore its link to dementia.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Delirium Confusion Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

Leiv Otto Watne

Oslo, Other, 0671, Norway

Location status: Recruiting

Location contact

Leiv O Watne, PhD

CONTACT

[email protected]

40203712

Leiv Otto Watne, MD

PRINCIPAL_INVESTIGATOR

About this study

Delirium is a common and serious complication to acute illness, and is characterized by acute disturbances in attention, awareness, and cognition. Dementia is a major risk factor of delirium, and delirium increases the risk of dementia progression and development. As the conditions share both clinical and epidemiological features, some researchers suggest that also pathophysiological links are shared. Understanding delirium pathophysiology, which is poorly understood, may thus help elucidate early molecular mechanisms in dementia.

This study aims to to increase our understanding of the pathophysiology of delirium and molecular links between delirium and dementia, by exploring cerebrospinal fluid (CSF) biomarkers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with acute hip fracture

Exclusion criteria

  • Moribund patients.
  • Lack of consent

Treatment and study plan

Hip fracture surgery

Procedure

Hip fracture surgery

Primary outcomes

  1. Delirium

    Time frame: Daily during hospital stay (pre-/and postoperatively) until 5 days after surgery (or discharge)

    Pre- and postoperative delirium

Secondary outcomes

  1. Dementia

    Time frame: Cognitive changes the first 48 months after inclusion

    Incident dementia

Study contacts

Contact information is provided by the study sponsor or research team.

Leiv O Watne, PhD

CONTACT

[email protected]

40203712

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Registry information

Official study title

MOLECULAR BIOMARKERS IN DELIRIUM AND DEMENTIA

Important dates

Study start
2016
Primary completion
2027
Study completion
2027
First posted
Sep 29, 2021
Registry last updated
Mar 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.